Vir Biotechnology ex-officer plans $242K sale

Vir Biotechnology, Inc. (VIR) is the issuer for a planned sale of common stock by Jason V. O'Byrne, identified as a former officer, under Rule 144.

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) is the issuer for a planned sale of common stock by Jason V. O'Byrne, identified as a former officer, under Rule 144. The notice covers up to 23,148 shares of common stock to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of $242,591.04. Vir Biotechnology reports 169,215,958 shares of common stock outstanding as of 08/25/2026. In the prior three months, Jason V. O'Byrne sold 25,000 shares for $245,297.50 on 08/21/2026 and 14,352 shares for $142,123.55 on 08/24/2026. The planned sale is in connection with a stock option exercise, with sales expected on or about 08/25/2026 on NASDAQ.

Key Figures

Shares to be sold: 23,148 shares Aggregate market value of securities to be sold: $242,591.04 Shares outstanding: 169,215,958 shares +3 more

6 metrics

Shares to be sold 23,148 shares Maximum Vir Biotechnology common shares covered by the Form 144 notice

Aggregate market value of securities to be sold $242,591.04 Value of the 23,148 shares covered by the Form 144

Shares outstanding 169,215,958 shares Vir Biotechnology common shares outstanding as of 08/25/2026

Recent sale 1 25,000 shares for $245,297.50 Sale of Vir Biotechnology common stock on 08/21/2026 by Jason V. O'Byrne

Recent sale 2 14,352 shares for $142,123.55 Sale of Vir Biotechnology common stock on 08/24/2026 by Jason V. O'Byrne

Approximate date of sale 08/25/2026 Planned sale date for shares covered by the Form 144 on NASDAQ

Key Terms

Rule 144, Form 144, Stock Option Exercise

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Stock Option Exercise financial

"Common | 08/25/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Vir Biotechnology, Inc. (VIR)?

The filing reports that a former officer, Jason V. O'Byrne, may sell up to 23,148 shares of Vir Biotechnology common stock under Rule 144. This is a planned resale by an affiliate and does not represent new share issuance by the company.

How many VIR shares are covered by this Form 144 notice?

The notice covers up to 23,148 shares of Vir Biotechnology, Inc. common stock. The aggregate market value of these shares is listed as $242,591.04 in the filing.

How many Vir Biotechnology (VIR) shares are outstanding as reported in this filing?

Vir Biotechnology, Inc. reports 169,215,958 shares of common stock outstanding as of 08/25/2026. This figure is a baseline share count and is separate from the shares that may be sold under this Form 144.

What past sales by Jason V. O'Byrne in VIR stock are disclosed?

The filing discloses that Jason V. O'Byrne sold 25,000 shares for $245,297.50 on 08/21/2026 and 14,352 shares for $142,123.55 on 08/24/2026. These sales are in Vir Biotechnology common stock.

What is the relationship of the selling holder to Vir Biotechnology (VIR)?

The selling holder, Jason V. O'Byrne, is identified as a Former Officer of Vir Biotechnology, Inc. The Form 144 relates to sales for his account via Fidelity Brokerage Services LLC.

On which market are the VIR shares in this Form 144 expected to be sold?

The shares covered by this Form 144 are expected to be sold on NASDAQ, as specified in the filing, with an approximate sale date of 08/25/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 11:07 AM Accepted by SEC EDGAR 08/25/2026 - 11:07 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001871145
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vir Biotechnology, Inc.
SEC File Number	001-39083
Address of Issuer	1800 OWENS STREET SUITE 900 SAN FRANCISCO CALIFORNIA 94158
Phone	415-906-4324
Name of Person for Whose Account the Securities are To Be Sold	O'Byrne Jason
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	23148	242591.04	169215958	08/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/25/2026	Stock Option Exercise	Issuer			23148	08/25/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	08/21/2026	25000	245297.50
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	08/24/2026	14352	142123.55

144: Remarks and Signature

Remarks
Date of Notice	08/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jessica Spraker, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jason V. O'Byrne.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)